14
Participants
Start Date
March 20, 2025
Primary Completion Date
July 31, 2026
Study Completion Date
January 31, 2027
semaglutide
Semaglutide is act as an adjunct to a reduced calorie diet and increase physical activity for chronic weight management in adult with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
RECRUITING
The University of Hong Kong, Department of Medicine, Hong Kong
The University of Hong Kong
OTHER